Advertisement

Search Results

Advertisement



Your search for ASCO,ASCO matches 21424 pages

Showing 1 - 50


gynecologic cancers

Upfront Radical Cytoreductive Surgery Extends Progression-Free Survival in Advanced Ovarian Cancer

The TRUST trial is the first phase III randomized study to show improved progression-free survival for primary cytoreductive surgery compared with interval surgery without compromising short-term or long-term quality of life, although the study failed to meet its primary endpoint of overall...

skin cancer

Four-Year Outcomes Highlight Efficacy of Neoadjuvant Nivolumab and Relatlimab in Advanced Resectable Melanoma

A neoadjuvant and adjuvant regimen of anti–PD-1 therapy with nivolumab and anti–LAG-3 therapy with relatlimab led to a 4-year event-free survival rate of 80% in patients with advanced, resectable melanoma, according to long-term findings from a phase II study published in the Journal of Clinical...

prostate cancer

New Research Offers Reassurance About Localized Prostate Cancer Prognosis

A recent study out of Sweden found that people diagnosed with nonmetastatic low-risk prostate cancer later in life were 90% more likely to survive their cancer for their remaining life expectancy if they were treated according to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Of...

hepatobiliary cancer

Chemoimmunotherapy for Advanced BTC: 3-Year Overall Survival Update From the TOPAZ Trial

In a follow-up analysis of the pivotal TOPAZ-1 study, which established the combination of the PD-L1 inhibitor durvalumab plus gemcitabine and cisplatin as the first-line treatment for advanced biliary tract cancer (BTC), researchers have shown that after 3 years, more than twice as many study...

skin cancer

RP1 Plus Nivolumab in Anti–PD-1–Resistant Advanced Melanoma

When combined with nivolumab, RP1 (vusolimogene oderparepvec), a genetically engineered herpes simplex virus type 1–based oncolytic immunotherapy, induced deep and durable systemic responses in patients with advanced melanoma who have failed to respond to prior anti–PD-1 therapy, according to...

gastroesophageal cancer

Literature Review Highlights Rising Incidence and Disparities in Many Early-Onset GI Cancers

Rates of early-onset gastrointestinal cancers, beyond just colorectal cancer, are rising among people younger than age 50, according to experts from Dana-Farber Cancer Institute. Researchers from Dana-Farber published a literature review in the British Journal of Surgery showing that cases of newly ...

head and neck cancer

AJCC Guideline Reassessment Aims to Improve HPV-Positive Throat Cancer Staging

An update of staging guidelines from the American Joint Committee on Cancer (AJCC) for human papillomavirus (HPV)-positive throat cancer—now more common in the United States than cervical cancer, according to the American Cancer Society—aims to make treatment of early-stage disease more consistent...

gynecologic cancers
geriatric oncology

Women Over the Age of 65 Still at Heightened Risk of HPV-Related Cervical Cancer

Women aged 65 years and older are still at a heightened risk of cervical cancer caused by human papillomavirus (HPV), suggest the findings of a large observational Chinese study published by Ye et al in Gynecology and Obstetrics Clinical Medicine. Most guidelines currently recommend discontinuing...

lung cancer
immunotherapy

Corticosteroids May Limit Efficacy of Immunotherapy in Patients With NSCLC

Corticosteroids, which are commonly prescribed to alleviate cancer-related symptoms in patients with non–small cell lung cancer (NSCLC) treated with immunotherapy, may be the reason certain immunotherapies fail in treating the disease, according to new research published by Polyakov et al in Cancer ...

issues in oncology
solid tumors

Study Supports Multi-Contaminant Water Treatment to Reduce Cancer Risk

Treating drinking water for multiple contaminants, especially arsenic and chromium-6, could prevent more than 50,000 cancer cases in the United States, according to the results of a study by the Environmental Working Group that was published in Environmental Research.  Study findings highlighted...

covid-19
survivorship

Adult Survivors of Childhood Cancer May Be at Increased Risk of Severe COVID-19 Infection

People who have survived cancer as children may be at a higher risk of developing severe COVID-19 infection—even decades after their cancer diagnosis, according to results published by Louro et al in The Lancet Regional Health – Europe. Thanks to medical advances, more and more children are...

leukemia

Can Planned C-Sections Increase the Risk of Childhood ALL?

Children born by planned cesarean section (C-section) may have an increased risk of developing acute lymphoblastic leukemia (ALL) later in life, according to a recent study published by Kampitsi et al in the International Journal of Cancer. Alhough the researchers did find an association, they...

breast cancer

BMI and Cardiovascular Disease Associated With Increased Breast Cancer Risk

Weight-associated risk for developing breast cancer after menopause may be higher among women with cardiovascular disease compared with those without cardiovascular disease and women with or without type 2 diabetes, according to the results of two prospective European cohort studies, which were...

breast cancer

Survey Finds Confusion Over Mammogram Guidelines

Mammograms can detect breast cancer early before symptoms appear, and regular screening decreases the risk of dying from breast cancer. But a recent survey conducted by the Annenberg Public Policy Center (APPC) of the University of Pennsylvania shows that some Americans appear to be confused about...

hepatobiliary cancer

Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable HCC

The U.S. Food and Drug Administration (FDA) has approved SIR-Spheres Y-90 resin microspheres, manufactured by Sirtex, for the treatment of unresectable hepatocellular carcinoma (HCC). With this approval, these microspheres become the only radioembolization therapy approved for the treatment of both ...

leukemia

Preclinical Leukemia Chip Platform Improves Evaluation of CAR T-Cell Therapies

Investigators have bioengineered an organotypic immunocompetent chip—a laboratory device that combines the physical structure of human leukemia bone marrow and a functioning immune system—to empower real-time spatiotemporal monitoring of CAR-T cell functionality for leukemias. The preclinical...

lung cancer

Air Pollution Linked to Distinct Genomic Signatures in Lung Cancers Among Never-Smokers

A large analysis of the mutational processes of lung cancers in never-smoker patients showed that exposure to fine-particulate air pollution was strongly associated with increased genomic changes, including in cancer-driving and cancer-promoting genetic mutations. Findings from the whole-genome...

lung cancer

FDA Grants Accelerated Approval to Sunvozertinib for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations

On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sunvozertinib (Zegfrovy), a selective EGFR tyrosine kinase inhibitor, for adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an...

gynecologic cancers

PPP2R1A Mutations Linked to Improved Immunotherapy Outcomes in Ovarian Clear Cell Carcinoma

  Patients with ovarian clear cell carcinoma harboring PPP2R1A mutations showed significantly improved survival when treated with immunotherapy compared with those without PPP2R1A mutations, according to study findings published in Nature.  Preclinical findings from the study also suggested that...

multiple myeloma

FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma

On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to linvoseltamab-gcpt (Lynozyfic), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of...

solid tumors
hematologic malignancies

Study Reveals Long-Term Consequences of Chemotherapy on Healthy Blood Cells

Many cytotoxic chemotherapy agents have long-term biological consequences, including premature aging of the cell population structure of healthy blood, the results of a study of the genetic effects of chemotherapy showed. These findings published in Nature Genetics may help to guide future...

breast cancer

Can Hormone Therapy Affect Breast Cancer Risk in Younger Women?

Investigators have found that two common types of hormone therapy may alter breast cancer risk in women before age 55. Women treated with unopposed estrogen hormone therapy (E-HT) were less likely to develop the disease than those who did not use this type of hormone therapy. Additionally, women...

breast cancer

AI-Enhanced PACT as a Noninvasive Breast Imaging Alternative

Panoramic photoacoustic computed tomography (PACT) with machine learning assistance could be a safe, noninvasive, and sensitive alternative to mammography, ultrasound, and magnetic resonance imaging (MRI) for breast cancer screening, according to study results that were published in Nature...

breast cancer

Erika Hamilton, MD, on Oral SERDs in Breast Cancer: State of the Science

Erika Hamilton, MD, Director, Breast Cancer Research at Sarah Cannon Research Institute, provides a look at “where we stand in 2025” in the field of oral selective estrogen receptor degraders (SERDs) for patients with estrogen receptor–positive, HER2-negative breast cancer. She discusses the first...

bladder cancer

utDNA May Help to Personalize Bladder Cancer Treatment

Results of a multi-institutional study published by St-Laurent et al in Science Direct revealed that testing urine-based tumor DNA (utDNA) may help to predict which patients with bladder cancer are at higher risk for recurrence after not responding to first-line treatment. The study analyzed utDNA...

solid tumors

Survey Shows Inaccuracies in U.S. Perceptions of Testicular Cancer

Only about 13% of U.S. adults correctly reported that testicular cancer is most common among men younger than 40, according to the results of a survey. The survey, commissioned by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research...

prostate cancer
bladder cancer
kidney cancer

Genitourinary Oncology Highlights: Treatment Advances in Renal Cell, Bladder, Urothelial, and Prostate Cancers

The 2025 ASCO Annual Meeting has officially concluded. Our sincere thanks to the global oncology community and ASCO for creating such a remarkable forum advancing cancer care. Here we highlight the most impactful updates in genitourinary tumors from this year’s meeting. Kidney Cancer: Long-Term...

issues in oncology
global cancer care

Study Finds About One in Six Chemotherapy Drugs in Sub-Saharan Africa Fails Quality Tests

About one in six tested chemotherapies in sub-Saharan Africa were found to have serious quality defects, according to the results of a study published in The Lancet Global Health.   Researchers assessed the appearance, packaging, and labeling of each cancer medication and measured the quantity of...

cns cancers

ASTRO Updates Guideline on Radiation Therapy for High-Grade Diffuse Glioma

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) focuses on the use of radiation therapy for adults with World Health Organization (WHO) grade 4 diffuse gliomas, a category that includes some of the most common and most aggressive primary brain tumors. The...

prostate cancer
symptom management

Botulinum Toxin and Scopolamine for Radiation-Induced Salivary Gland Toxicity in Metastatic Prostate Cancer

Injection with botulinum toxin (BTX) type A (IncoA) plus transdermal scopolamine led to the reduction in radiation-induced salivary gland toxicity without compromising PSMA (prostate-specific membrane antigen) tumor uptake in patients with metastatic prostate cancer who were receiving...

colorectal cancer
immunotherapy

Predictive Biomarker Under Study in Colorectal Cancer

Researchers have uncovered a biomarker that may determine response to cytokine-induced killer-cell therapy and survival in patients with colorectal cancer, according to a recent study published by Li et al in The Journal of Immunology. Background Colorectal cancer is the second-leading cause of...

solid tumors
genomics/genetics

Best Practice Recommendations for Clinical Homologous Recombination Deficiency Testing

The Association for Molecular Pathology has introduced best practice recommendations for clinical laboratories developing and performing homologous recombination deficiency testing, according to new guidelines published by Hsiao et al in The Journal of Molecular Diagnostics. Background Homologous...

leukemia

Dual Menin and KAT6A/7 Inhibition Improves Outcomes in NUP98-Rearranged Pediatric AML Models

A combination of menin inhibition and KAT6A/7 inhibition significantly improved survival for NUP98-rearranged pediatric acute myeloid leukemia (AML) in AML model systems, even in menin inhibitor–resistant cells, according to findings published in Cancer Discovery. The MYST gene family histone...

hematologic malignancies

Adding the Hepcidin Mimetic Rusfertide to the Standard of Care Yields Benefits in Polycythemia Vera

In patients with polycythemia vera requiring frequent phlebotomies, the investigational hepcidin mimetic rusfertide, given as a weekly subcutaneous injection, more than doubled the clinical response rate and significantly improved quality of life in the global phase III VERIFY study.1 These...

gynecologic cancers

Mailed Self-Collection HPV Tests Improve Cervical Cancer Screening Rates, Study Finds

Mail-in self-collection tests for human papillomavirus (HPV) more than doubled cervical cancer screening participation among never- and under-screened U.S. women, according to a first-of-its-kind study from researchers at The University of Texas MD Anderson Cancer Center. In the real-world,...

The Ohio State Appoints Christian Rolfo, MD, PhD, MBA, to Lead Division of Medical Oncology

Christian Rolfo, MD, PhD, MBA, has been appointed Director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James). He will assume this position on August 15. Dr. Rolfo will ...

lung cancer

I Was Expecting to Hear I Have Heart Disease, Not Cancer

In 2022, I had a computed tomography (CT) coronary calcium scan to see whether there were any signs of narrowing or blockage in my heart arteries. Heart disease runs in my family. My father died of a heart attack the year before, and I worried that I was at risk for the same fate. It was a complete ...

W. Kimryn Rathmell, MD, PhD, FASCO, Selected for Women Who Conquer Cancer Mentorship Award

W. Kimryn Rathmell, MD, PhD, FASCO, has been selected for the prestigious 2025 Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award. Launched in 2016, the Women Who Conquer Cancer award program honors extraordinary women leaders in oncology and role models who have excelled as mentors...

William C. Wood, MD, FASCO, Renowned Surgeon, Esteemed Mentor, Global Academic Dean, Dies at 84

William C. “Bill” Wood, MD, FASCO, a leader and mentor in the field of breast cancer, died on August 18, 2024. He was 84. Dr. Wood was the J.B. Whitehead Professor and Chair of the Department of Surgery at Emory University School of Medicine from 1991 to 2009. He chaired the 1990 U.S. National...

Malignant Hematology Expert and Medicare Reimbursement Advocate, Samuel M. Silver, MD, PhD, FRCP, FASCO, MACP, Dies at 74

The ASCO Post would like to pay tribute to Samuel M. Silver, MD,PhD, FRCP, FASCO, MACP, who died on August 14, 2024, at the age of 74. Dr. Silver was renowned in the hematology and oncology community and a respected member of the editorial advisory board of The ASCO Post. Additionally, he served...

Minnesota Society of Clinical Oncology Recognized for Advocacy at 2025 ASCO Annual Meeting

The Minnesota Society of Clinical Oncology (MSCO) is the recipient of the 2024 Jeffery C. Ward Affiliate Advocacy Award. The Association for Clinical Oncology presented the award during the State Affiliates’ Reception at the 2025 ASCO Annual Meeting. Presented annually, the Jeffery C. Ward...

Number of Cancer Survivors in the United States Reaches 18.6 Million and Projected to Exceed 22 Million by 2035

The number of people living with a history of cancer in the United States is estimated at 18.6 million as of January 1, 2025, and projected to exceed 22 million by 2035, according to a new report, Cancer Treatment and Survivorship Statistics, 2025, led by the American Cancer Society (ACS). The...

colorectal cancer

Chinese Herbal Medicine for Improving Adjuvant Chemotherapy Completion in Patients With Colon Cancer

Guest Editor’s Note: Although guidelines recommend adjuvant combination chemotherapy for patients with stage II and III colon cancer who are at high risk of disease recurrence, fewer than 50% complete treatment because of fear of adverse effects or symptom burden. The herbal formula Jianpi Bushen ...

breast cancer

Preoperative Endocrine Therapy for Older Women With Estrogen Receptor–Positive Breast Cancer: Impact on Radiotherapy Decisions

Providing a brief, 90-day course of preoperative endocrine therapy to older women with early-stage, estrogen receptor–positive, invasive breast cancer may significantly alter both patient preferences and physician recommendations regarding adjuvant radiation therapy, according to data presented...

hematologic malignancies

HLA-Matching Considerations for Hematopoietic Cell Transplantation in Hematologic Malignancies

Besides relapse of the malignant disease, graft-vs-host disease is still one of the greatest concerns, in terms of adverse effects, following a hematopoietic cell transplantation (HCT) in a patient with a hematologic malignancy. To mitigate these concerns, investigators are continually analyzing ...

ASCO Honors Karen Eubanks Jackson of Sisters Network® Inc. With 2025 Patient Advocate Award

Karen Eubanks Jackson, founder and Chief Executive Officer of Sisters Network® Inc. (SNI), has been named the recipient of the 2025 Patient Advocate Award by ASCO, Conquer Cancer, and the ASCO Foundation. The awards ceremony was held during the 2025 ASCO Annual Meeting. (See a video with Ms....

breast cancer

Vepdegestrant vs Fulvestrant in Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer

Based on the findings of the VERITAC-2 trial, treatment with the selective PROTAC (proteolysis targeting chimera) estrogen receptor degrader vepdegestrant yielded statistically significant and clinically meaningful improvement in progression-free survival in patients with ESR1-mutant, estrogen...

issues in oncology

ASCO and Medicaid: Advocacy In Action

The Association for Clinical Oncology (ASCO) is actively engaged in advocacy to protect Medicaid access for millions of Americans. Members can support ASCO’s Medicaid advocacy efforts through the ACT Network. In 2025, ASCO has partnered with other health-care organizations and engaged with...

National Comprehensive Cancer Network Launches NCCN Guidelines Navigator

The National Comprehensive Cancer Network® (NCCN®) has announced a new, interactive digital delivery format for the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The NCCN Guidelines® are the recognized standard for clinical decision-making and policy in cancer care and are the...

breast cancer

ASCO Guideline Update Calls for Omission of SLNB in Select Patients With Early-Stage Breast Cancer

ASCO has released a clinical practice guideline update on the role of sentinel lymph node biopsy (SLNB) in early-stage breast cancer.1 The update includes recommendations based on findings from trials released after the published guideline in 2017, including data from nine randomized trials...

Advertisement

Advertisement




Advertisement